PATCH Act
- Sponsor
- Sen. Kennedy, John [R-LA]
- Committees
- Banking, Housing, and Urban Affairs Committee (primary)
- Last action
- May 21, 2026
Bottom line
The PATCH Act aims to remove medical debt as a factor in consumer credit reporting and lending decisions, potentially improving credit scores for individuals with such debt.
What it actually does
This bill, known as the PATCH Act, amends the Fair Credit Reporting Act (FCRA) to prohibit consumer reporting agencies from including any adverse information related to medical debt on a consumer report. It also mandates the Bureau of Consumer Financial Protection (BCFP) to issue regulations preventing creditors from using medical debt information when making credit extension decisions. The bill defines medical debt as any debt arising from medical services, products, or devices.
Proponents argue
Proponents argue that medical debt is often unexpected and involuntary, unlike other forms of debt, and should not negatively impact a consumer's creditworthiness. They contend that excluding medical debt from credit reports will prevent individuals from being penalized for health-related financial hardships, improving access to housing, employment, and other financial services, and reducing the overall burden of healthcare costs on consumers.
Opponents contend
Opponents, particularly some creditors and credit reporting agencies, might argue that all forms of debt, including medical debt, are relevant indicators of a consumer's financial responsibility and ability to repay. They may contend that removing this information could obscure a complete financial picture, potentially increasing risk for lenders and leading to higher interest rates or stricter lending standards for all consumers, or that it could incentivize non-payment of medical bills.
The bill is very short and clear, making it highly accessible for any reader to understand its core provisions.
Section 2(a)
Definition of "Medical Debt"
This section adds a new definition to the Fair Credit Reporting Act (FCRA), specifying that "medical debt" refers to any financial obligation incurred from receiving medical services, products, or devices. This broad definition ensures that various forms of healthcare-related debt are covered by the bill's protections, from hospital bills to costs for medical equipment.
Supporters argue
Supporters contend that a clear and comprehensive definition of medical debt is crucial to ensure consistent application of the new protections, preventing loopholes that could allow certain types of medical-related financial burdens to still appear on credit reports.
Critics contend
No specific opposition is typically raised against the definition itself, assuming the broader policy goal is accepted. However, some might argue that the definition is too broad, potentially encompassing debts that are not truly "unexpected" or "involuntary."
Tradeoffs
The tension lies in defining the scope of protection; a broad definition protects more consumers but might also include debts that some argue should be considered in credit decisions, balancing consumer relief with perceived financial transparency.
Section 2(b)(1)
Prohibition on Reporting Adverse Medical Debt Information
This provision amends the FCRA to explicitly prohibit consumer reporting agencies from including any adverse information related to medical debt on a consumer report. This includes medical debts that have been sent to collections, charged off as losses, or subjected to similar actions. It clarifies that while agencies can collect this information, they cannot use it to negatively impact a consumer's credit report.
Section 3
Prohibition on Creditor Use of Medical Debt Information
This section directs the Bureau of Consumer Financial Protection (BCFP) to amend its regulations within one year to prohibit creditors from obtaining or using any information related to a consumer's medical debt when deciding whether to extend credit. This goes beyond credit reporting agencies and directly restricts how creditors can use such information, even if they obtain it through other means, ensuring a comprehensive shield for consumers.
This subparagraph clarifies that the prohibition on reporting adverse medical debt information does not prevent consumer reporting agencies from *collecting* the information.
Section 2(b)(1)(B)
Why it matters:This is standard legislative practice to clarify the scope of a prohibition and avoid unintended consequences (e.g., preventing agencies from even holding the data for internal, non-reporting purposes). It ensures the prohibition is specifically on *reporting adversely* rather than *data possession*.
Case for: Allows consumer reporting agencies to maintain data for internal analysis, compliance, or future policy changes without impacting consumer credit reports. It ensures the prohibition is specifically on *reporting adversely* rather than *data possession*.
Case against: Critics might argue that allowing agencies to collect the data still poses a risk of misuse or future re-introduction of reporting, even if currently prohibited. They might prefer a complete erasure of such data from agency records to fully protect consumer privacy.
Estimated impact: Minimal direct impact on consumers as long as the reporting prohibition is enforced. Primarily affects internal operations of credit reporting agencies by allowing them to retain data for non-reporting purposes.
Makes technical and conforming amendments to Section 604(g) of the FCRA, removing outdated references to how medical information (specifically medical contact information) was previously treated under the old Section 605(a)(6).
Section 2(b)(2)
Why it matters:This is standard legislative practice to ensure consistency across related statutes when a core provision is amended. It's necessary to update cross-references and remove obsolete language to prevent confusion or conflicting interpretations.
Case for: Ensures the FCRA remains internally consistent and removes obsolete language, preventing confusion or conflicting interpretations that could arise from outdated statutory references.
Case against: No specific opposition to these technical amendments themselves, as they merely align the statute with the primary policy change and do not introduce new policy substance.
Estimated impact: No direct impact on consumers, but essential for legal clarity and proper implementation of the main prohibition by ensuring the statute is coherent.